These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 21804321)
1. [Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway]. Funakoshi-Tago M Yakugaku Zasshi; 2011; 131(8):1183-7. PubMed ID: 21804321 [TBL] [Abstract][Full Text] [Related]
2. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972 [TBL] [Abstract][Full Text] [Related]
3. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis. Ueda F; Tago K; Tamura H; Funakoshi-Tago M J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978 [TBL] [Abstract][Full Text] [Related]
4. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation. Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641 [TBL] [Abstract][Full Text] [Related]
5. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice. Abe M; Funakoshi-Tago M; Tago K; Kamishimoto J; Aizu-Yokota E; Sonoda Y; Kasahara T Int Immunopharmacol; 2009 Jul; 9(7-8):870-7. PubMed ID: 19327411 [TBL] [Abstract][Full Text] [Related]
6. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs. Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005 [TBL] [Abstract][Full Text] [Related]
7. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484 [TBL] [Abstract][Full Text] [Related]
8. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053 [TBL] [Abstract][Full Text] [Related]
9. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR. Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963 [TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644 [TBL] [Abstract][Full Text] [Related]
13. The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells. Bongartz H; Hessenkemper W; Müller C; Fensky M; Fritsch J; Mandel K; Behrmann I; Haan C; Fischer T; Feller SM; Schaper F Cell Signal; 2017 Jul; 35():37-47. PubMed ID: 28365441 [TBL] [Abstract][Full Text] [Related]
14. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant]. Funakoshi-Tago M Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718 [TBL] [Abstract][Full Text] [Related]
15. Aberrant signal transduction pathways in myeloproliferative neoplasms. Kota J; Caceres N; Constantinescu SN Leukemia; 2008 Oct; 22(10):1828-40. PubMed ID: 18769448 [TBL] [Abstract][Full Text] [Related]
16. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689 [TBL] [Abstract][Full Text] [Related]
17. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways. Shi J; Yuan B; Hu W; Lodish H Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563 [TBL] [Abstract][Full Text] [Related]
18. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Wernig G; Gonneville JR; Crowley BJ; Rodrigues MS; Reddy MM; Hudon HE; Walz C; Reiter A; Podar K; Royer Y; Constantinescu SN; Tomasson MH; Griffin JD; Gilliland DG; Sattler M Blood; 2008 Apr; 111(7):3751-9. PubMed ID: 18216297 [TBL] [Abstract][Full Text] [Related]
19. An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2 Rabadan Moraes G; Pasquier F; Marzac C; Deconinck E; Damanti CC; Leroy G; El-Khoury M; El Nemer W; Kiladjian JJ; Raslova H; Najman A; Vainchenker W; Marty C; Bellanné-Chantelot C; Plo I Br J Haematol; 2022 Jul; 198(1):131-136. PubMed ID: 35355248 [TBL] [Abstract][Full Text] [Related]